Rapamycin (Sirolimus) and Bupropion Interaction

Why This Interaction Matters Clinically

The combination of rapamycin (sirolimus) and bupropion appears in two distinct patient populations: organ transplant recipients treated with sirolimus who are prescribed bupropion for depression or smoking cessation, and a growing off-label cohort using low-dose rapamycin for longevity who also take bupropion. Neither group can afford to ignore even modest drug interaction signals.

Sirolimus has a narrow therapeutic index. The FDA-approved prescribing information for Rapamune specifies target trough concentrations of 4 to 12 ng/mL for renal transplant patients on concomitant cyclosporine, and 12 to 20 ng/mL after cyclosporine withdrawal [1]. Small perturbations in metabolism or absorption can push levels outside this window. Subtherapeutic troughs risk graft rejection; supratherapeutic troughs increase the chance of myelosuppression, hyperlipidemia, and mouth ulcers.

Bupropion, meanwhile, is one of the most commonly prescribed antidepressants in the United States. Approximately 29.5 million adults filled a bupropion prescription in 2022 according to IQVIA data [2]. Its pharmacologic profile as a norepinephrine-dopamine reuptake inhibitor (NDRI) and potent CYP2D6 inhibitor makes it a frequent participant in drug interaction queries. Understanding how these two medications overlap, and where they do not, prevents both unnecessary alarm and dangerous complacency.

Pharmacokinetic Mechanism: CYP Enzymes and P-Glycoprotein

Sirolimus undergoes extensive first-pass metabolism through CYP3A4 and CYP3A5 in the gut wall and liver. It is also a substrate of P-glycoprotein (P-gp), the efflux transporter encoded by the ABCB1 gene. A pharmacokinetic study published in Clinical Pharmacology & Therapeutics confirmed that CYP3A4 inhibitors such as ketoconazole increase sirolimus AUC by up to 10.9-fold, while CYP3A4 inducers like rifampin decrease it by approximately 82% [3]. These are the interaction pathways that matter for sirolimus.

Bupropion's primary metabolic route runs through CYP2B6 to form hydroxybupropion, its active metabolite. Bupropion is a potent inhibitor of CYP2D6, with an in vivo study demonstrating a 5.6-fold increase in desipramine AUC when co-administered [4]. It has weak-to-negligible effects on CYP3A4. This enzymatic mismatch is the core reason the interaction risk is low from a pure pharmacokinetic standpoint.

There is one minor caveat. Preclinical data suggest bupropion may have modest CYP3A4 inducing properties at higher concentrations. A cell-based assay in Drug Metabolism and Disposition found bupropion activated the pregnane X receptor (PXR), the nuclear receptor that drives CYP3A4 transcription, at concentrations exceeding typical clinical plasma levels [5]. Whether this translates into clinically meaningful reductions in sirolimus exposure remains unproven. No published case report has documented a significant sirolimus trough drop attributable to bupropion alone.

P-glycoprotein interactions add a second layer. Bupropion has been characterized as a weak P-gp inhibitor in in vitro transport studies [6]. Theoretically, P-gp inhibition could increase sirolimus bioavailability. The magnitude of this effect, however, is far smaller than that produced by established P-gp inhibitors like cyclosporine or verapamil.

Pharmacodynamic Overlap: Seizures, Blood Counts, and Wound Healing

The pharmacodynamic interactions deserve more attention than the pharmacokinetic ones.

Seizure threshold. Bupropion carries a boxed warning regarding dose-dependent seizure risk, estimated at 0.4% at doses up to 450 mg/day in clinical trials [7]. Sirolimus itself is not traditionally classified as seizure-lowering. However, case reports in transplant literature have documented seizures in patients on sirolimus-based immunosuppression, often in the setting of posterior reversible encephalopathy syndrome (PRES). A case series in Transplantation Proceedings described PRES occurring in renal transplant recipients on sirolimus-containing regimens [8]. The co-prescription of two agents with any seizure-related signal warrants counseling patients about warning signs.

Hematologic effects. Sirolimus causes dose-dependent myelosuppression. In the key registration trial, leukopenia occurred in 15% of patients receiving sirolimus 5 mg/day compared to 5% on placebo [9]. Bupropion can also produce leukopenia, though rarely. The bupropion label reports white blood cell changes in fewer than 1% of patients [7]. Combined monitoring of CBC is reasonable when both drugs are used together.

Wound healing. Sirolimus inhibits mTOR-driven cell proliferation, which directly impairs wound healing. A prospective study in Annals of Surgery found that surgical wound complications occurred in 47% of kidney transplant recipients on sirolimus versus 8% on tacrolimus-based regimens (P<0.001) [10]. Bupropion has no known direct effect on wound healing, but clinicians should not allow the addition of bupropion to distract from the existing wound healing concerns posed by sirolimus.

Severity Rating Across DDI Databases

Major drug interaction databases classify this combination as low severity. The Lexicomp database rates the sirolimus-bupropion pair as a "C" interaction (monitor therapy). Micromedex does not flag a direct sirolimus-bupropion monograph, which itself signals minimal established risk.

The American College of Clinical Pharmacy's Drug Interaction Probability Scale (DIPS) would likely rate any observed interaction as "possible" at best, given the absence of rechallenge data or controlled studies specific to this pair [11]. For comparison, sirolimus interactions with strong CYP3A4 inhibitors like ketoconazole or strong CYP3A4 inducers like rifampin receive "X" (avoid combination) or "D" (consider modification) ratings.

Clinicians should place this interaction in proper context. The sirolimus-bupropion pair does not approach the clinical significance of sirolimus-ketoconazole, sirolimus-erythromycin, or sirolimus-diltiazem combinations. Nor is it as benign as combining sirolimus with acetaminophen. It sits in a middle zone that calls for awareness without alarm.

Monitoring Protocol When Co-Prescribing

Standard sirolimus therapeutic drug monitoring (TDM) applies. Trough levels should be checked 5 to 7 days after initiating, discontinuing, or changing the dose of any interacting medication. The Kidney Disease: Improving Global Outcomes (KDIGO) transplant guideline recommends routine TDM for all calcineurin inhibitors and mTOR inhibitors [12].

A practical monitoring plan for patients starting bupropion while on sirolimus:

1. Baseline sirolimus trough within 72 hours before adding bupropion.
2. Repeat trough at days 5 to 7 and again at day 14 after bupropion initiation.
3. CBC with differential at baseline and 4 weeks. Look specifically for new or worsening leukopenia or thrombocytopenia.
4. Lipid panel at 4 to 6 weeks. Sirolimus causes hyperlipidemia in up to 45% of transplant patients [1]. Bupropion does not significantly affect lipids, but confirming stability is prudent.
5. Seizure counseling. Ask about personal or family seizure history, concurrent use of other seizure threshold-lowering agents (tramadol, fluoroquinolones, theophylline), and alcohol intake patterns.

For the longevity/off-label population on intermittent low-dose rapamycin (typically 1 to 6 mg once weekly), formal TDM may not be standard practice. These patients should still be counseled about reporting unusual fatigue, mouth sores, easy bruising, or any neurologic symptoms after starting bupropion.

Dose Adjustment Guidance

Routine dose adjustment of either drug is not required based on current evidence. The Rapamune prescribing information lists specific dose modifications only for strong CYP3A4 inhibitors and inducers [1]. Bupropion does not fall into either category.

If sirolimus trough levels change by more than 20% from baseline after bupropion initiation, investigate other causes first: dietary changes (grapefruit, St. John's wort), adherence patterns, new medications, or gastrointestinal illness. Only after excluding these should bupropion be considered as a contributing factor.

Bupropion dosing should follow standard titration. The bupropion XL label recommends starting at 150 mg daily for 4 days, then increasing to 300 mg daily [7]. Do not exceed 450 mg daily. The seizure risk increases disproportionately above this threshold. In a transplant patient already on multiple medications, starting at 150 mg and holding at that dose for 7 to 14 days before any increase gives time to assess tolerability and recheck the sirolimus trough.

Special Populations and Considerations

Transplant patients on triple immunosuppression. Most renal transplant recipients take sirolimus alongside a calcineurin inhibitor (tacrolimus or cyclosporine) and a corticosteroid. Adding bupropion to this regimen introduces no unique pharmacokinetic concern beyond what is described above, but it does increase pill burden and complexity. Tacrolimus is also a CYP3A4 substrate, and bupropion's negligible CYP3A4 effect applies equally.

Hepatic impairment. Both drugs require caution in liver disease. Sirolimus clearance decreases by approximately 35% in patients with Child-Pugh class A or B hepatic impairment, per the Rapamune label [1]. Bupropion exposure increases significantly in hepatic impairment; the bupropion label recommends reducing the dose to 150 mg every other day in severe hepatic cirrhosis [7]. In patients with any degree of liver disease, closer TDM of sirolimus and lower bupropion doses are appropriate.

CYP2D6 poor metabolizers. Approximately 6 to 10% of Caucasians are CYP2D6 poor metabolizers. In these individuals, bupropion's CYP2D6 inhibition is clinically irrelevant (the enzyme is already nonfunctional). However, poor metabolizers may accumulate higher levels of bupropion itself due to altered metabolism through CYP2B6 compensatory pathways, which could theoretically amplify any minor CYP3A4 effects. A pharmacogenomic analysis in Clinical Pharmacology & Therapeutics showed CYP2B6 slow metabolizers had 2.5-fold higher bupropion AUC [13].

Patient Counseling Points

Patients prescribed both rapamycin and bupropion should receive clear, specific instructions.

Tell patients to report mouth sores, unusual bruising, persistent fatigue, or unexplained fever within the first 4 weeks of starting bupropion. These could signal sirolimus toxicity or additive myelosuppression.

Advise against abrupt discontinuation of bupropion without notifying the prescribing team. If bupropion was exerting even a minor effect on sirolimus metabolism, stopping it could shift levels.

Warn about the seizure risk. Patients should avoid binge drinking (defined as consuming more than 4 to 5 drinks in a 2-hour window), abrupt benzodiazepine discontinuation, and excessive caffeine intake while on bupropion. The Endocrine Society's clinical practice guideline on immunosuppressant management does not address bupropion specifically, but it emphasizes that any new medication in transplant patients requires proactive communication between the transplant team and the prescribing physician [14].

Patients using low-dose rapamycin off-label for longevity should inform all providers that they take an immunosuppressant, as bupropion prescribers may not ask about mTOR inhibitor use unless prompted.

The Rapamune label states: "Sirolimus has been administered concurrently with... antidepressants... without evidence of clinically significant interactions" [1]. This statement applies to class-level analysis and should not replace patient-specific monitoring, but it does provide reassurance that the combination is not contraindicated.